title: Managing large cell lymphoma.
abstract: Rituximab has greatly improved standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, but prospects remain poor in patients with adverse risk factors. We need to know whether the addition of rituximab also improves the efficacy of more intensive treatments and how to use molecular profiling to guide us in introducing other novel agents.
authors.affiliation: Institute for Hematology, Hôpital Saint Louis, Paris, France. christian.gisselbrecht@sls.ap-hop-paris.fr
authors.forename: C
authors.initials: C
authors.lastname: Gisselbrecht
authors.forename: N
authors.initials: N
authors.lastname: Mounier
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000628:therapy*; D033581:Stem Cell Transplantation